People · Operator
Named in public records as an officer, director or promoter · active 2017–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zomedica Pharmaceuticals Corp. | — | Pharmaceuticals | Series A | $25.6M | $371.7M | 2017 |
Bruk Herbst at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bruk Herbst on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephanie Morley | 1 | 3 |
| Jeffrey Rowe | 1 | 3 |
| William MacArthur | 1 | 2 |
| Jim Lebar | 1 | 2 |
| James LeBar | 1 | 1 |
| James Le Bar | 1 | 1 |
| Jane J. Eagleson | 1 | 1 |
| Robert J. DiMarzo | 1 | 1 |
| Thomas J. Robitaille | 1 | 1 |
| Tom J. Robitaille | 1 | 1 |
| Gerald Solensky | 1 | 1 |
| Shameze Rampertab | 1 | 1 |
| Rodney J. Williams | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.